| Objective: Based on the original study on the prognostic value of androgen receptor(AR)in patients with triple-negative breast cancer(TNBC)in English databases,the prognostic value of AR expression in TNBC patients was investigated by systematic evaluation and meta-analysis.Methods: The studies that investigated the association between AR expression and prognosis in patients diagnosed with TNBC,and published on PubMed,Embase,the Cochrane Library,and references of articles up to May 2019 were searched.The search terms were "Triple Negative Breast Neoplasms" or "Triple Negative Breast cancer" in combination with "Receptors,Androgen" or "Androgens".The hazard ratio(HR)and confidence interval(CI)of disease-free survival(DFS),overall survival(OS),Distant disease-free survival(DDFS),and Recurrence free survival(RFS)were weighted and pooled by using the fixed-effect or random-effect model based on the heterogeneity of included studies.Results: A total of 27 studies,including 4914 TNBC patients were included.AR was expressed in 27.96%(1315/4703)of TNBC patients.15(55.56%)studies reported DFS data,23(85.19%)studies reported OS data,4(14.81%)studies indicated RFS data and 3(11.11%)studies showed DDFS data.In addition,AR expression in TNBC was not associated with disease free survival(DFS)(HR=0.923,95% CI: 0.671-1.271,p=0.634),overall survival(OS)(HR=0.910,95% CI: 0.678-1.222,p=0.531),Distant disease-free survival(DDFS)(HR=1.02,95%CI:0.96-1.08,p=0.489)and Recurrence free survival(RFS)(HR=0.957,95% CI:0.462-1.982,p=0.906)in TNBC,regardless of confounding factors and heterogeneity existed among included studies.Conclusion: In TNBC patients,AR expression is not associated with prognosis. |
PDF Full Text Request